JP2012519484A5 - - Google Patents

Download PDF

Info

Publication number
JP2012519484A5
JP2012519484A5 JP2011552950A JP2011552950A JP2012519484A5 JP 2012519484 A5 JP2012519484 A5 JP 2012519484A5 JP 2011552950 A JP2011552950 A JP 2011552950A JP 2011552950 A JP2011552950 A JP 2011552950A JP 2012519484 A5 JP2012519484 A5 JP 2012519484A5
Authority
JP
Japan
Prior art keywords
mir
sequence
seq
mre
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011552950A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012519484A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/000709 external-priority patent/WO2010101663A2/en
Publication of JP2012519484A publication Critical patent/JP2012519484A/ja
Publication of JP2012519484A5 publication Critical patent/JP2012519484A5/ja
Pending legal-status Critical Current

Links

JP2011552950A 2009-03-06 2010-03-08 マイクロrna応答要素を含む弱毒化生インフルエンザウイルスワクチン Pending JP2012519484A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15823309P 2009-03-06 2009-03-06
US61/158,233 2009-03-06
PCT/US2010/000709 WO2010101663A2 (en) 2009-03-06 2010-03-08 Live attenuated influenza virus vaccines comprising microrna response elements

Publications (2)

Publication Number Publication Date
JP2012519484A JP2012519484A (ja) 2012-08-30
JP2012519484A5 true JP2012519484A5 (enExample) 2013-04-25

Family

ID=42710158

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011552950A Pending JP2012519484A (ja) 2009-03-06 2010-03-08 マイクロrna応答要素を含む弱毒化生インフルエンザウイルスワクチン

Country Status (5)

Country Link
US (1) US8883995B2 (enExample)
EP (1) EP2403527A4 (enExample)
JP (1) JP2012519484A (enExample)
CA (1) CA2754826A1 (enExample)
WO (1) WO2010101663A2 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1629105B1 (en) 2003-04-29 2010-09-01 AVI BioPharma, Inc. Compositions for enhancing transport and antisense efficacy of nucleic acid analog into cells
US8067571B2 (en) 2005-07-13 2011-11-29 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
US8877206B2 (en) 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
US20100016215A1 (en) 2007-06-29 2010-01-21 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
AU2009236306B2 (en) 2008-04-17 2015-04-02 Pds Biotechnology Corporation Stimulation of an immune response by enantiomers of cationic lipids
WO2010101663A2 (en) * 2009-03-06 2010-09-10 Mount Sinai School Of Medicine Of New York University Live attenuated influenza virus vaccines comprising microrna response elements
US20110269665A1 (en) 2009-06-26 2011-11-03 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
WO2011131193A1 (en) * 2010-04-24 2011-10-27 Statens Serum Institut Diagnosing and treating fibrotic diseases using micro-rna 17
EP3333265B1 (en) 2010-05-14 2020-02-05 Oregon Health & Science University Recombinant hcmv and rhcmv vectors encoding a heterologous antigen isolated from hepatitis b virus and uses thereof
WO2012051491A1 (en) * 2010-10-14 2012-04-19 The United States Of America, As Represented By The Secretary National Institutes Of Health Compositions and methods for controlling neurotropic viral pathogenesis by micro-rna targeting
US9168236B2 (en) * 2011-04-08 2015-10-27 Institut National De La Santé Et De La Recherche Médicale (Inserm) Methods and pharmaceutical compositions for inhibiting influenza viruses replication
US9161948B2 (en) 2011-05-05 2015-10-20 Sarepta Therapeutics, Inc. Peptide oligonucleotide conjugates
SMT201800284T1 (it) 2011-06-10 2018-07-17 Univ Oregon Health & Science Glicoproteine cmv e vettori ricombinanti
WO2013059498A1 (en) * 2011-10-18 2013-04-25 Geovax, Inc. Mva vectors expressing polypeptides and having high level production in certain cell lines
EP3536789A1 (en) * 2012-06-06 2019-09-11 Boehringer Ingelheim International GmbH Cell engineering using rnas
US10286064B2 (en) * 2012-06-15 2019-05-14 Pds Biotechnology Corporation Cationic lipid vaccine compositions and methods of use
TWI672149B (zh) 2012-09-21 2019-09-21 美商Pds生技公司 改良之疫苗組成物及使用方法
SI2964769T1 (sl) 2013-03-05 2018-12-31 Oregon Health & Sccience University Citomegalovirusni vektorji, ki omogočajo krmiljenje ciljanja T-celic
JP6445523B2 (ja) * 2013-03-15 2018-12-26 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 生体分子アジュバントを含むワクチン
CN104694541A (zh) * 2013-12-09 2015-06-10 江苏命码生物科技有限公司 禽流感病毒miRNA及其鉴定、检测和应用
WO2015195881A1 (en) * 2014-06-18 2015-12-23 The Regents Of The University Of California Methods and compositions for inhibiting infection by influenza and viruses
KR102205348B1 (ko) 2014-07-16 2021-01-20 오레곤 헬스 앤드 사이언스 유니버시티 외인성 항원을 포함하는 인간 시토메갈로바이러스
EP3207127A4 (en) * 2014-10-14 2018-06-06 Texas Tech University System Live attenuated viral vaccine created by self-attenuation with species-specific artificial microrna
JP6620294B2 (ja) * 2014-12-03 2019-12-18 公益財団法人ヒューマンサイエンス振興財団 ムンプスウイルスの弱毒化方法、ムンプスウイルス、及び、生ワクチン
CN114317611A (zh) 2015-02-10 2022-04-12 俄勒冈健康与科学大学 可用于产生非典型cd8+t细胞应答的方法和组合物
US11020417B2 (en) 2015-06-04 2021-06-01 Sarepta Therapeutics, Inc Methods and compounds for treatment of lymphocyte-related diseases and conditions
US10927151B2 (en) 2015-06-09 2021-02-23 Sanofi Pasteur Inc. Methods of optimizing nucleotide sequences encoding engineered influenza proteins
US10383935B2 (en) 2015-09-23 2019-08-20 Regents Of The University Of Minnesota Methods of making and using live attenuated viruses
US10086063B2 (en) 2015-09-23 2018-10-02 Regents Of The University Of Minnesota Methods of making and using live attenuated viruses
EP4092112A1 (en) 2015-11-13 2022-11-23 PDS Biotechnology Corporation Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy
AU2016355468B2 (en) * 2015-11-20 2022-12-15 Oregon Health & Science University CMV vectors comprising microRNA recognition elements
JP7046848B2 (ja) * 2016-07-08 2022-04-04 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 弱毒化突然変異体ジカウイルスをコードするゲノム配列
CN110036112B (zh) 2016-10-18 2024-05-10 俄勒冈健康与科学大学 引发受主要组织相容性复合体e分子限制的t细胞的巨细胞病毒载体
JP7432506B2 (ja) 2017-10-30 2024-02-16 武田薬品工業株式会社 脂質エンベロープウイルスを不活化するための環境適合性の界面活性剤
AU2018378588A1 (en) 2017-12-05 2020-06-25 Pds Biotechnology Corporation Methods and compositions comprising cationic lipids for stimulating type 1 interferon genes
US12178869B2 (en) 2017-12-22 2024-12-31 Codagenix Inc. Recombinant virus with codon-pair deoptimized region and uses thereof for the treatment of cancer
RU2020132280A (ru) 2018-03-08 2022-04-11 Кодадженикс Инк. Аттенуированные флавивирусы
WO2019204571A1 (en) 2018-04-20 2019-10-24 Texas Tech University System Self-attenuated prophylactic and therapeutic vaccines against pathogens
WO2020244605A1 (zh) * 2019-06-04 2020-12-10 凌斌 重组非结构蛋白1、含此的重组流感病毒及免疫组成物及其用于制备流感病毒疫苗组成物的用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4939055B2 (ja) 2002-11-13 2012-05-23 トマス ジェファソン ユニバーシティ 癌の診断および治療のための組成物および方法
NZ542935A (en) * 2003-04-23 2008-08-29 Wisconsin Alumni Res Found Recombinant influenza viruses holding a mutation in a transmembrane protein gene
US8145436B2 (en) * 2003-07-15 2012-03-27 The Trustees Of The University Of Pennsylvania Method and systems for identifying micro-RNA targets and synthesizing novel micro-RNAs and uses of the same
US8106180B2 (en) 2003-08-07 2012-01-31 Whitehead Institute For Biomedical Research Methods and products for expression of micro RNAs
US7279275B2 (en) 2003-11-03 2007-10-09 Washington University Methods and compositions for detection of segmented negative strand RNA viruses
AU2005287395A1 (en) 2004-07-02 2006-03-30 Henry L. Niman Copy choice recombination and uses thereof
US20070213293A1 (en) 2005-04-08 2007-09-13 Nastech Pharmaceutical Company Inc. Rnai therapeutic for respiratory virus infection
US20070054872A1 (en) * 2005-08-24 2007-03-08 Mirus Bio Corporation Regulatable or conditional expression systems
US20080045472A1 (en) * 2006-03-31 2008-02-21 Council Of Scientific And Industrial Research Bharat Biotech Targets for human micro rnas in avian influenza virus (h5n1) genome
US9072701B2 (en) 2006-04-21 2015-07-07 St. Jude Children's Research Hospital Avian influenza viruses, vaccines, compositions, formulations, and methods
WO2008140622A2 (en) * 2006-12-22 2008-11-20 The Penn State Research Foundation Modified polymerases and attenuated viruses and methods of use thereof
CN101646769A (zh) 2007-02-20 2010-02-10 孟山都技术公司 无脊椎动物微rna
CN103476425B (zh) * 2007-03-30 2015-07-15 纽约州州立大学研究基金会 用于疫苗的减毒病毒
EP2527472B1 (en) * 2007-05-31 2016-09-28 Yale University A genetic lesion associated with cancer
WO2009079592A2 (en) * 2007-12-17 2009-06-25 California Institute Of Technology Modulating immune system development and function through microrna mir-146
WO2009111892A1 (en) * 2008-03-14 2009-09-17 Ottawa Health Research Institute Microrna mediated oncolytic targeting
WO2010101663A2 (en) * 2009-03-06 2010-09-10 Mount Sinai School Of Medicine Of New York University Live attenuated influenza virus vaccines comprising microrna response elements

Similar Documents

Publication Publication Date Title
Menon et al. miRNA: a promising therapeutic target in cancer
Tenoever RNA viruses and the host microRNA machinery
HRP20190992T1 (hr) Suprimiranje gena za huntingtin inducirano s rnai
Drury et al. The clinical application of microRNAs in infectious disease
Booton et al. Emerging role of MicroRNAs and long noncoding RNAs in respiratory disease
JP5652830B2 (ja) マイクロrna制御組換えワクシニアウイルス及びその使用
Wei et al. MyD88 as a target of microRNA-203 in regulation of lipopolysaccharide or Bacille Calmette-Guerin induced inflammatory response of macrophage RAW264. 7 cells
ZA202003137B (en) Nucleic acid, composition and conjugate containing same, and preparation method and use
Zhang et al. Induction of the cellular miR-29c by influenza virus inhibits the innate immune response through protection of A20 mRNA
WO2013090457A3 (en) In vivo delivery of oligonucleotides
Bela-ong et al. Involvement of two microRNAs in the early immune response to DNA vaccination against a fish rhabdovirus
WO2012149646A1 (en) Mirna inhibitors and their uses
BR112017007923A2 (pt) método para produzir manipulação genética mediada por reações multiplex com rna em uma célula receptora, construção de ácido nucleico, cassete de expressão, vetor, célula receptora, célula geneticamente modificada, tecido, planta ou animal, progênie de planta ou animal e método para modificar um sítio alvo no genoma de uma célula
WO2013166264A2 (en) Methods for altering virus replication
Samir et al. MicroRNAs in the host response to viral infections of veterinary importance
Ramadan et al. MicroRNA signatures in the pathogenesis and therapy of inflammatory bowel disease
CN104651364B (zh) 一种竞争性消耗致癌性microRNAs的LncRNA、溶瘤腺病毒及其用途
Abo-Al-Ela The emerging regulatory roles of noncoding RNAs in immune function of fish: MicroRNAs versus long noncoding RNAs
Shirvani et al. RETRACTED: Non-coding RNA in SARS-CoV-2: Progress toward therapeutic significance
JP2014516530A5 (enExample)
CN101402945A (zh) 表达抗传染性法氏囊病病毒微小rna重组禽腺联病毒的制备方法
Li et al. Inhibition of influenza A virus replication by RNA interference targeted against the PB1 subunit of the RNA polymerase gene
US10383935B2 (en) Methods of making and using live attenuated viruses
Yakovlev The Role of miRNA in differentiation, cell proliferation, and pathogenesis of poultry diseases
Goher et al. The interplay between MDV and HVT affects viral miRNa expression